Salix Pharmaceuticals Ltd. (SLXP)
-NasdaqGS 60.39 
0.70(1.17%) 25 May 04:00 SGT|After Hours
:
60.13 0.26 (0.44%) 25 May 04:11 SGT
| Prev Close: | 59.69 |
|---|
| Open: | 59.82 |
|---|
| Bid: | 59.72 x 100 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 58.93 |
|---|
| Beta: | 0.81 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 59.50 - 60.85 |
|---|
| 52wk Range: | 37.52 - 60.85 |
|---|
| Volume: | 490,474 |
|---|
| Avg Vol (3m): | 530,573 |
|---|
| Market Cap: | 3.70B |
|---|
| P/E (ttm): | 49.66 |
|---|
| EPS (ttm): | 1.22 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Salix Stock Hits New 52-Week High (SLXP)at TheStreet(Sat, 25 May)
- Positive Data from Synergy PharmaZacks(Fri, 24 May)
- New Diagnostic Solution from RocheZacks(Fri, 24 May)
- SALIX PHARMACEUTICALS LTD Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Fri, 24 May)
- Pfizer Halts Inotuzumab StudyZacks(Fri, 24 May)
- Data on AstraZeneca's NaloxegolZacks(Fri, 24 May)
- Repros to Conduct Phase IIb TrialZacks(Fri, 24 May)
- Don't Get Too Worked Up Over Salix Pharmaceuticals's Latest Numbersat Motley Fool(Fri, 24 May)
- Positive Data on Roche CandidateZacks(Thu, 23 May)
- Data on Merck KGaA's L-BLP25Zacks(Thu, 23 May)
Key Statistics
| Forward P/E (1 yr): | 13.45 |
|---|
| P/S (ttm): | 4.77 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 3.39 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.80 |
|---|
| Mean Recommendation*: | 2.2 |
|---|
| PEG Ratio (5 yr expected): | 0.86 |
|---|
Business Summary
Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs and medical devices used in the treatment of various gastrointestinal diseases in the United States.
View More